Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

NCT00773240 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT00773240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00773240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
Lead sponsor
ALK-Abelló A/S
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
February 28, 2009
Enrollment
276 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grass pollen allergy